Aptose Biosciences (NASDAQ:APTO – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Institutional and Insider Ownership
26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 4.6% of Aptose Biosciences shares are held by insiders. Comparatively, 0.2% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Aptose Biosciences and Gilead Sciences”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Aptose Biosciences | N/A | N/A | -$51.21 million | ($6.20) | -0.06 |
Gilead Sciences | $27.81 billion | 3.81 | $5.67 billion | $0.36 | 236.25 |
Profitability
This table compares Aptose Biosciences and Gilead Sciences’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Aptose Biosciences | N/A | -5,683.22% | -279.77% |
Gilead Sciences | 3.79% | 29.34% | 10.10% |
Risk and Volatility
Aptose Biosciences has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Aptose Biosciences and Gilead Sciences, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Aptose Biosciences | 0 | 0 | 4 | 0 | 3.00 |
Gilead Sciences | 0 | 10 | 9 | 1 | 2.55 |
Aptose Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 2,270.92%. Gilead Sciences has a consensus price target of $84.83, suggesting a potential downside of 0.25%. Given Aptose Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Aptose Biosciences is more favorable than Gilead Sciences.
Summary
Gilead Sciences beats Aptose Biosciences on 10 of the 14 factors compared between the two stocks.
About Aptose Biosciences
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.